Company ProfilePremium

Jilin Joinature Polymer Co., Ltd.

Company Profile Analysis

Ticker: 688716.SS吉林省中研高分子材料股份有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Jilin Joinature Polymer Co., Ltd. - Company showcase

Year Founded & Workforce

2006

464 Employees

Jilin Joinature Polymer Co., Ltd. logo

Jilin Joinature Polymer Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Jilin Joinature Polymer Co., Ltd. Overview

Jilin Joinature is China's largest producer of polyetheretherketone (PEEK), the high-performance semi-crystalline thermoplastic that replaces metal in demanding automotive, electronics, industrial, energy, medical-implant and aerospace parts. By its own account it was the world's fourth producer to reach 1,000-tonne annual PEEK capacity, after Victrex (UK), Solvay/Syensqo (Belgium) and Evonik (Germany). It was also the second producer globally, after Victrex, to polymerise PEEK in 5,000-litre reactors. In 2025 it sold more than 1,000 tonnes for the first time (1,079.84 t, +11.84%) with a design capacity of 1,000 t/y running at 102% utilisation, and it claims domestic volumes now exceed Victrex's in China. Revenue is small (CNY 309 M in FY2025). Profitability has compressed sharply because of subsidiary build-out and R&D, even as gross margin rose to 44%. The investment case now rests on a CNY 1.2 bn, 10,000 t/y PEEK plus 2,000 t/y monomer integrated complex in Zhangjiagang, Jiangsu. That project would raise capacity elevenfold into a market facing a wave of domestic capacity additions.


Company's own description (FY2024 annual report summary, paraphrased and translated)

The company describes itself as a high-tech enterprise focused on the R&D, production and sale of PEEK. It says more than a decade of in-house development has produced breakthroughs in PEEK synthesis, purification and composite reinforcement. It claims fully domestic, full-process production capability covering five areas: key raw-material selection, process control, equipment design, process optimisation and indicator monitoring. It cites an appraisal organised by the China Synthetic Resin Association concluding that its main product performance indicators reach international advanced level and fill a domestic gap, and that its industrial-scale PEEK technology leads in China.

Its products are resin-form PEEK organised as "two categories, three grades, seven series" with 89 specifications (FY2024). This expanded from 52 specifications in "six series" in earlier descriptions (Morningstar profile).

Two categories: pure resin, and composite-reinforced resin (glass fibre or carbon fibre).

Three melt-flow grades: 770, 550 and 330, from low to high flow.

Seven series: coarse powder (P), fine powder (PF), pellets (G), glass-fibre pellets (GL), carbon-fibre pellets (CA), wear-resistant pellets (FC), and application-customised products. The company also sells a small volume of finished PEEK parts.

Business model and revenue model

Revenue model: almost 100% product sales of PEEK resin and compounds, priced per tonne. There is no material service, subscription or licensing revenue. A small "PEEK products" line (finished parts, partly sourced from fabricators as samples and partly sold by the Shenzhen subsidiary) was under 2% of main-business revenue in 2023–2025 (derived from Inquiry Reply).

Pricing mechanism: at the start of each year the company sets guide prices for each grade based on cost, market conditions and strategy. These are not adjusted intra-year absent major raw-material or market shifts. Order prices are negotiated off the guide price by customer type, competitive situation, relationship history, volume and payment terms (Inquiry Reply, Q1). Rebates in kind are used: some customers stocked up in 2025 "to obtain better in-kind rebates".

Unit economics: average selling price (ASP) fell from CNY 321,900/t (2023) to CNY 287,000/t (2024) after a deliberate price cut. It was broadly stable in 2025; the derived ASP is about CNY 286,000/t on 1,079.84 t. Gross margin nonetheless rose from 39.48% (2023) to 40.08% (2024) and 44.05% (2025). The driver was cost: the main monomer, 4,4'-difluorobenzophenone (DFBP or "fluoroketone"), makes up roughly 50% of coarse-powder cost, and its purchase price fell 33.53% (2024) and 3.28% (2025). Production-line automation also lowered consumption per tonne (Inquiry Reply).

Value-chain position

Joinature sits in the polymerisation and compounding stage:

Upstream (purchased): DFBP from Zhejiang Zhongxin Fluoride Materials, Xinhan New Materials and Xingfu New Materials, plus hydroquinone, diphenyl sulfone, sodium carbonate, and carbon and glass fibres. About 0.7–0.8 t of DFBP is consumed per tonne of PEEK (Inquiry Reply).

Midstream (core): polymerisation, purification and drying into coarse powder; then grinding into fine powder, melt-filtration into pellets, or compounding into GF, CF or wear grades.

Downstream (customers): extruders, injection moulders, compression moulders and coaters who make stock shapes, film, wire, monofilament and parts.

Forward integration under way: a Shenzhen PEEK application and processing centre (parts), a Shanghai CF/PEEK composite R&D centre, and an extrusion profile line.

Backward integration planned: 2,000 t/y of PEEK monomer capacity within the Zhangjiagang project.

Customer types and end-markets

Customer types: stock-shape ("profile", 型材) extruders, which the company says are currently its largest revenue group. Others are injection moulders, compression moulders, coaters, compounders, traders and distributors, and medical-device OEMs.

Named customers and partners: BYD; Xi'an Kangtuo Medical; Weigao Orthopaedics; Dabo Medical; Guangzhou Medprin (Inquiry Reply; FY2024 annual report).

Customer concentration (Inquiry Reply, Q2): - Top-5 customer share: 43.99% (2023), 36.84% (2024), 33.34% (2025).

  • Top-10 customer share: 57.97% (2023), 49.40% (2024), 50.27% (2025).

End-markets cited by the company: automotive and transport (including NEV motor enamelled wire and battery seals), electronics and semiconductors (CMP retaining rings, wafer carriers, phone fixtures, speaker diaphragms), industrial machinery and energy (seals, compressor valve plates, bearings), medical implants, aerospace, humanoid robots and the low-altitude economy, and 3D printing (Longbridge profile; FY2024 AR; Inquiry Reply).

Independent characterisation

Joinature is best understood as a single-polymer, sub-scale specialty-chemicals manufacturer that has won the Chinese industrial-grade PEEK market on cost and availability. It is now trying to move up-mix (medical, semiconductor, aerospace) and up-scale (10 kt) simultaneously.

Strengths: a decade-plus of process know-how, a proven 5,000 L reactor process, high utilisation and rising gross margins.

Weaknesses: its customer base is still dominated by price-sensitive stock-shape extruders. Its premium-segment penetration (medical-implant revenue was only CNY 5.17 M cumulatively over 2023–2025) is embryonic. Its overseas share is below 1%.

Profit trend: reported profitability has collapsed from CNY 54.6 M (2023) to CNY 11.9 M (2025) and a CNY 13.0 M loss in H1 2026, as operating expenses scale ahead of revenue.

Investment profile: the business is effectively a capacity-expansion option on Chinese PEEK demand, funded largely by IPO cash and prospective bank debt.

Strategy

Stated strategy themes (FY2024/FY2025 annual reports; Inquiry Reply)

"Full industrial chain, high-end, scale" (全产业链、高端化、规模化): the stated medium- to long-term strategy. It means integrating backward into monomer, scaling to 10 kt+, and shifting the mix to medical, semiconductor and aerospace grades.

Import substitution and "plastic replacing steel": capturing China's roughly 1,100 t/y of PEEK imports (2024) and metal-replacement demand.

Application-led growth: opening new end-uses such as NEV 800 V motor wire, humanoid robots, the low-altitude economy, 3D printing and hydrogen equipment.

"Quality, efficiency, returns" action plan (提质增效重回报): sustained cash dividends and investor communication (H1 2025 board notice; FY2025 AR).

Medical focus for margin: management says the downstream layout will favour medical "from a gross-margin perspective", while stock-shape customers dominate revenue today (CLS, May 2026).

Initiative register (last 24 months)

DateInitiativeDetailStatus
Jul 2024Shanghai CF/PEEK composite R&D centre (new subsidiary)Relocated and re-scoped IPO projectCompleted
2,024Shenzhen PEEK application and processing centreDownstream fabrication and application supportOperating; loss-making
Jun 2024PEEK-LISCIEX medical master fileNMPA registration M2024156-000Six devices registered using the material
Jul 2024Medical R&D capitalisation beginsCNY 2.52 M (2024), CNY 5.40 M (2025) capitalisedOngoing; project end Jun 2028
2024–2025Production-line automation upgradeLower unit consumption, better batch consistencyCompleted (cited for 2025 cost decline)
2,025European expansionDQS audit, European warehouse, new EU and Taiwan customersIn progress
2,025Humanoid-robot PEEK parts R&DCNY 3.52 M spent in 2025Partial adoption
2,025Monomer localisation pilot (合成聚芳醚酮原料国产化中试) and "F4422" projectCNY 10.78 M and CNY 5.19 M R&D in 2025; aimed at self-supply of key raw materialsLab-to-pilot scale-up
Apr 2026K.D. Feddersen European distributionZyPEEK across EuropeActive
28 Apr 2026Private placement to chairman (≤CNY 303 M for working capital)Priced at CNY 26.35Terminated 17 Jul 2026
14 May 2026Zhangjiagang 10 kt PEEK plus 2 kt monomer projectTotal ≈ CNY 1,157.6 M (preliminary): construction CNY 970.8 M, capitalised interest CNY 54.0 M, working capital CNY 132.8 MPre-approval; subsidiary formed Jul 2026
30 Jul 2026Share buybackCNY 50–100 M at ≤CNY 48.94; 3 months; up to CNY 90 M bank-loan backedIn progress (no progress report verified)

Medium-term targets and guidance

No formal revenue or profit guidance: A-share STAR companies rarely publish it.

Capacity target: 11,000 t/y total (1,000 existing plus 10,000 new), phased over 2–4 years.

Funding plan: about CNY 510 M of new long-term bank debt. Pro-forma liabilities/assets would rise to about 35% (about 30% had the placement proceeded). Assumed interest is about CNY 17.85 M per year (2027–2029), capitalised during construction (Inquiry Reply Q7).

Post-completion fixed-cost burden: about CNY 66.5 M per year of depreciation plus CNY 2.1 M of amortisation, about 22% of FY2025 revenue.

Quality ambition: product purity and batch consistency to "catch up with and surpass" Victrex.

Products & Services

All products are sold under the ZyPEEK brand. Grades are built on three base melt-flow families: 770 (low flow, high toughness, the flagship "770G" pellet), 550 (medium) and 330 (high flow, for thin-wall injection). Specific pricing is not publicly disclosed. The group ASP was about CNY 287,000/t in 2024 (Inquiry Reply).

Pure resin category

Product seriesDescriptionKey properties / processingTarget customers & usesStatus / notes
Coarse powder (P series)First-stage product after polymerisation, purification and dryingFeedstock for all other series; can be melt-filtered, ground or compoundedCompounders and some processors; mostly consumed internallyExternal sales curtailed in 2025 (CNY 11.55 M revenue)
Fine powder (PF series), incl. ultra-fine powderGround coarse powderCompression moulding; powder and water-based coatingsCompression moulders and coaters: seal rings, gaskets, gears; chemical pipe linings, bearing cages, non-stick cookware coatings, textile rollers, food mouldsFastest growing in 2025 (+38%); highest pure-resin margin (54%); "ultra-fine" grades noted as high-growth (FY2025 AR)
Pellets (G series), flagship 770GMelt-extruded and melt-filtered coarse powderUniform pellets, low gel, low impurities; extrusion and injectionExtruders and moulders: monofilament, cable, film, stock shapes; phone-manufacturing fixtures, earphone diaphragms, gears, instrument tubing, cable clipsCore product (CNY 180.9 M, 2025)

Composite-reinforced category

Product seriesDescriptionKey propertiesUsesStatus
Glass-fibre reinforced (GL series)PEEK plus glass fibreHigh strength and toughnessCompressor valve plates, piston rings, seal rings, chemical pump bodies, valvesWithin composite revenue (CNY 86.4 M, 2025)
Carbon-fibre reinforced (CA series)PEEK plus selected carbon fibreHigh strength, wear resistance, thermal conductivityAuto functional parts (gaskets, pumps, transmission parts, bearings, valve plates), HV/LV electrical parts, chemical containers, pipes, valves; compressor, textile and medical partsSame
Wear-resistant (FC series)PEEK plus CF, PTFE and graphiteSelf-lubricating, very high wear resistance, slightly lower strength than CABearings and bushesSame

Application-customised series (FY2024 AR)

ProductDescription / targetStatus
Ceramic-modified PEEKSpecialty compoundCommercial (scale not disclosed)
Consumer-electronics gradesFor phone and earphone components, fixturesCommercial
Wafer-carrier gradesSemiconductor wafer handlingGeneration-one wafer-box and anti-static products in pilot stage (Inquiry Reply Q5)
Anti-static profile gradesESD-safe stock shapes for electronics and semiconductorsPilot / early commercial
Coloured PEEKPigmented gradesCommercial
PEEK-LISCIEX implant-grade PEEKMedical implant grades (ZR3G, ZR7G, ZR7) made in a 1,140.72 m² Class-10,000 GMP clean workshop with ISO 13485 certificationNMPA master file registered Jun 2024. Six registered medical devices use the material; small-batch shipments began H2 2025. Cumulative 2023–2025 revenue CNY 5.17 M. Implant-grade 3D-printing filament and short-CF-reinforced grades are close to completing biocompatibility evaluation (Inquiry Reply Q5; GTJA HK)
Radiation-resistant PEEKFor nuclear-power coils and windingsMass production; passed irradiation testing; cumulative 2023–2025 revenue CNY 28.92 M

PEEK products (fabricated parts) and new platforms

OfferingDescriptionStatus
Fabricated PEEK parts (Shenzhen)Injection-moulded, extruded and machined partsCapable of most standard parts; 2025 margin 5.17%
PEEK stock-shape extrusion lineProfiles (rod, plate)Line built (Inquiry Reply Q5)
PAEK pilot linePolyaryletherketone for aerospacePilot line built; small-batch trial production
CF/PEEK unidirectional prepregContinuous carbon-fibre composite tape for aerospace and orthopaedicsTrial production; company was lead drafter of a related group standard
Humanoid-robot PEEK partsJoint and reducer components"Some applications successfully introduced", others in co-development

Financial Narrative

All figures are CNY M under PRC Accounting Standards (CAS), consolidated, audited annual figures. Sources: cfi.cn financial-indicator pages (republished filings); FY2024 flash results (STCN, 26 Feb 2025); FY2024 AR summary; Inquiry Reply; IPO prospectus data via Jiemian and Chinabaogao.

Income statement

Notes: - FY2023 revenue is derived from FY2024 revenue of CNY 277 M (−5.05% YoY) and agrees with R&D/revenue of 7.91%. FY2023 COGS and gross profit are derived from the 39.48% gross margin.

  • FY2023 pre-tax and net profit are derived from the FY2024 flash (pre-tax −27.74%, net −27.99%). cfi.cn shows FY2023 net profit as CNY 0.55 bn rounded.

  • FY2022 net profit is CNY 0.56 bn rounded (cfi.cn). FY2021 deducted net profit of CNY 47.18 M is from the prospectus (Jiemian).

  • FY2024 EPS is derived (39.29 / 121.68 M shares).

Margins and growth

Revenue CAGR FY2021–FY2025: 11.1% (derived; 203.0 → 309.2). FY2019–FY2022 revenue was CNY 112 M, 158.2 M, 203.0 M and 248.1 M (prospectus via Jiemian and Chinabaogao).

Quarterly trajectory (most recent six quarters)

Derived from cumulative cfi.cn figures (H1 2025 revenue 131.28 / NP 7.03; 9M 2025 207.03 / 10.43; FY2025 309.22 / 11.87; Q1 2026 65.63 / −4.81; H1 2026 131.66 / −12.96). Q1 2025 net profit is derived from the disclosed −185.04% YoY decline in Q1 2026.

Balance sheet

Sources: cfi.cn (FY2025 balances); cfi.cn quote page (net assets 2022–2025); Inquiry Reply Q1 and Q6 (inventory, prepayments). FY2024 prepayments are derived from the FY2025 balance of CNY 17.11 M (+101.19%).

Debt. The company does not break out total borrowings in the sources retrieved.

  • At end-2025, bank credit facilities totalled CNY 682.0 M, of which CNY 119.27 M was drawn. This included a CNY 37.0 M fixed-asset loan; the balance is likely trade-finance instruments (Inquiry Reply Q7).

  • FY2025 financing cash inflow was CNY 55.6 M, indicating new borrowing.

  • At end-2025, gross cash plus short-term wealth products comfortably exceeded borrowings, so net cash was large and positive (estimated > CNY 400 M at end-Q1 2026).

  • Goodwill: none (no acquisitions). Intangibles include capitalised medical-PEEK development of CNY 2.52 M (2024) and CNY 5.40 M (2025).

Cash flow

Note: Gross investing flows are inflated by rolling wealth-management products (FY2025 inflows CNY 4.35 bn, outflows CNY 4.56 bn). Pure capex and free cash flow are not separately verified.

Management explains the negative FY2025 operating cash flow by heavy use of bills: bank acceptance bills received, endorsed and discounted are excluded from operating cash flow under its policy. It says operating cash flow "adjusted" for these would be positive, and that Q1 2026 OCF turned positive (Investor Q&A, fxbaogao). Analysts should treat this with caution, because H1 2026 OCF was again negative (−CNY 16.0 M).

Key ratios

Derived. FY2023 ROE is depressed by IPO equity arriving in September (average-equity basis). The FY2024 payout ratio is disclosed (61.95%). The FY2025 payout (CNY 24.34 M ÷ CNY 11.87 M) is derived.

Not computable from verified data: ROIC, current ratio, net debt/EBITDA, interest coverage, cash conversion cycle and EBITDA. Depreciation is not disclosed in the retrieved sources. Interest expense is immaterial given the net-cash position.

Commentary — trends, inflections, drivers

  1. Growth phase (2019–2023). Revenue rose from CNY 112 M to about CNY 292 M (≈27% CAGR) as China adopted domestic PEEK and Joinature scaled toward 1,000 t. Margins were healthy: net margins of about 19–23%.

  2. Price-for-volume inflection (2024). Facing "intensifying domestic competition and international political-economic changes", management cut prices about 11% (ASP CNY 321.9k → 287.0k/t). Revenue fell 5%. Gross margin still edged up because DFBP costs fell 34%, but net profit fell 28% as opex rose with the IPO-funded expansion.

  3. Volume recovery with profit collapse (2025). Volume rose 11.84% to 1,079.84 t and revenue rose 11.6%. Gross margin rose to 44.05%. However, opex growth overwhelmed gross profit:

    • Total operating cost rose to CNY 302.0 M (97.7% of revenue).

    • R&D investment jumped 48% to CNY 47.2 M.

    • Shanghai and Shenzhen subsidiaries ran losses.

    • Spending on HR systems, brand, digitalisation and lean management increased (GTJA HK).

    • Net profit fell 70%.

  4. Losses (H1 2026). Revenue was flat at CNY 131.7 M even as gross margin rose to 50.64% in Q1 2026. The company lost CNY 13.0 M as subsidiary headcount (hired from Q2 2025) burdened costs without matching revenue. The key inflection to monitor is whether revenue growth resumes before the Zhangjiagang capex cycle adds about CNY 68.6 M per year of depreciation and amortisation.

  5. Balance-sheet quality. Leverage is very low (liabilities about 10.5% of assets). The company carries no goodwill and no inventory write-downs. The SSE challenged the absence of write-downs given inventory turnover of about 1.1–1.4x; management defended it on high margins and long shelf life. Semi-finished inventory nearly tripled from 2023 to 2025 (CNY 18.3 M → 50.8 M).

  6. Capital allocation tension. The company paid more in dividends (CNY 24.3 M) than it earned in FY2025, is buying back stock (CNY 50–100 M, partly bank-funded), and plans about CNY 510 M of new debt for the 10 kt project. Those three commitments compete for the same cash pile.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityLocationRoleStatus / notesSource

Jilin Joinature Polymer Co., Ltd. (parent)

Changchun, Jilin

Polymerisation, compounding, sales, medical GMP workshop

Parent-only FY2025 revenue CNY 306.64 M; net profit CNY 52.08 M

Inquiry Reply Q1

Zhongyan Composites (Shanghai) Technology Development Co. ("中研上海")

Shanghai

Carbon-fibre/PEEK composite R&D centre (IPO project)

Established 2024; loss-making start-up phase; centre completed

Board notice Jul 2024; CLS

Zhongyan Shenzhen ("中研深圳")

Shenzhen, Guangdong

PEEK application and processing centre; small parts sales

Established 2024; loss-making start-up phase

Inquiry Reply Q1; GTJA HK note

Zhongyan Top Polymer Materials (Jiangsu) Co. ("中研拓普")

Zhangjiagang, Jiangsu

Vehicle for 10 kt PEEK plus 2 kt monomer project

Approved 17 Jul 2026; CNY 100 M registered capital

CLS 17 Jul 2026

Houhe Medical device R&D centre ("厚和医疗器械研发中心")

Not specified

Medical-device R&D (IPO project)

In construction; part of remaining CNY 104 M IPO spend

Inquiry Reply Q7

Revenue by Segment

Product category (CNY Mn)FY2023FY2024FY2025

Pure resin – total

211.59196.44216.54

Pure resin – pellets (G)

170.18151.56180.87

Pure resin – fine powder (PF)

20.0517.4324.12

Pure resin – coarse powder (P)

21.3627.4611.55

Composite-reinforced (GL/CA/FC)

78.4676.7786.38

PEEK products (derived residual)

1.803.896.29

Main-business revenue (derived)

291.85277.10309.21

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Gross margin (%)

Gross margin (%)FY2023FY2024FY2025

Pure resin pellets

37.6134.5639.37

Pure resin fine powder

44.8850.0353.96

Pure resin coarse powder

33.3642.1248.41

Composite-reinforced

43.2847.1953.35

PEEK products

—56.075.17

Company gross margin

39.4840.0844.05

Share of main-business revenue (%)

Share of main-business revenue (%)FY2023FY2024FY2025

Pure resin

72.5070.8970.03

Composite-reinforced

26.8927.7127.93

PEEK products

0.611.402.04

YoY growth (%)

YoY growth (%)FY2024FY2025

Pellets

-10.9419.34

Fine powder

-13.0938.38

Coarse powder

28.57-57.94

Composite-reinforced

-2.1512.52

Sell-through ratio (%)

Sell-through ratio (%)FY2024FY2025Q1 2026

Pure resin pellets

95.60112.1045.89

Composite-reinforced

90.6684.9183.39

Pure resin fine powder

71.7582.9197.59

Pure resin coarse powder (external)

9.004.170.69

Income Statement and Per-Share Data

Metric (CNY Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

203.0248.1291.9277.0309.2

Cost of revenue

——176.7166.0173.0

Gross profit

——115.2111.0136.2

Operating profit

————17.2

Pre-tax profit

——60.043.415.9

Net profit attributable

—56.054.639.311.9

Net profit excl. non-recurring items

47.2—41.024.64.9

Non-recurring items

———14.77.0

R&D investment (expensed + capitalised)

——23.131.947.2

Basic EPS (CNY)

———0.320.10

Diluted EPS (CNY)

———0.320.10

Dividend per share (CNY)

——0.200.200.20

Margin Analysis (%)

Ratio (%)FY2021FY2022FY2023FY2024FY2025

Revenue growth

28.322.217.7-5.111.6

Gross margin

——39.4840.0844.05

Operating margin

————5.6

Pre-tax margin

——20.615.75.1

Net margin

—22.618.714.23.8

R&D / revenue

——7.9111.5215.25

Income Statement

Metric (CNY Mn)Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue

64.5666.7275.75102.1965.6366.03

Net profit attributable

5.661.373.401.44-4.81-8.15

Balance Sheet

Metric (CNY Mn)FY2022FY2023FY2024FY2025

Total assets

———1,338.2

Total liabilities

———154.2

Shareholders' equity

327.01,157.01,172.01,184.0

Cash & cash equivalents (year-end)

———331.6

Inventory – raw materials

—101.458.857.7

Inventory – self-made semi-finished

—18.341.550.8

Prepayments

——8.517.1

Share capital

—121.68121.68121.68

Capital reserve

———887.4

Retained earnings

———143.1

Balance Sheet and Margin Analysis (%)

Metric (CNY Mn)31 Mar 202630 Jun 2026

Total assets

1,302.11,281.9

Total liabilities

122.9135.1

Equity

1,179.21,146.7

Cash & cash equivalents

349.6243.7

Trading financial assets (structured deposits / wealth products)

175.0—

Liabilities / assets (%)

9.4410.54

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

Metric (CNY Mn)FY2024FY2025

Operating cash flow

—-37.7

Investing cash flow

—-211.3

Financing cash flow

—28.4

Dividends paid (for prior year)

24.324.3

Share buybacks

00

Cash Flow (9M 2025–H1 2026)

Metric (CNY Mn)9M 2025Q1 2026H1 2026

Operating cash flow

-56.71.3-16.0

Investing cash flow

-94.6-21.1-59.9

Financing cash flow

24.2-0.2-12.1

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025

ROE (%)

7.43.41.0

ROA (%)

——0.9

Inventory turnover (x)

1.411.091.21

Liabilities / assets (%)

——11.5

Dividend payout (%)

44.661.95205.0

Region (H1 2024) Overview

Region (H1 2024)Revenue (CNY Mn)Share (%)Gross margin (%)

Mainland China

129.096.340.15

Overseas

5.03.740.42

Share Price History

DatePriceCommentSource

20 Sep 2023

29.66

IPO price

IPO notice

25 Apr 2025

37.31

Market cap CNY 4.54 bn; P/E (TTM) 101x

Moomoo

28 May 2025

35.98

Market cap ≈ EUR 368 M; P/E 112.6x

finanzen.net

Late Jun 2026

36.57

+10.18% session

cfi.cn

24 Jul 2026

24.70

20-day fall ≥20%; below 50% of 1-year high close (implying a 1-year high close above CNY 49.4)

Buyback notice

10 Aug 2026

29.08

1-year return −25.95%

Disfold

Share Price & Returns

PeriodReturnBasis

Since IPO (to 10 Aug 2026)

-2.0%

29.08 vs 29.66 (derived)

1-year (to 10 Aug 2026)

-25.95%

Disfold

Annualised since listing

-5.07%

Lixinger (mid-2026)

Valuation Snapshot

MultipleValueBasis

Market cap

≈CNY 3.54 bn

121.68 M shares

P/E (FY2025)

≈291x

EPS CNY 0.10

P/E (TTM to H1 2026)

Negative

TTM NP ≈ −CNY 8.1 M (derived)

P/B

≈3.1x

Equity CNY 1,146.7 M (30 Jun 2026)

EV / Sales (FY2025)

≈9.7x

EV ≈ CNY 3.0 bn after ≈CNY 0.5 bn net cash (approximate)

EV / EBITDA

Not computable

EBITDA not disclosed

Dividend yield

≈0.7%

CNY 0.20 / 29.08

Analyst Ratings & Targets

DateBrokerRatingTheme

14 Sep 2025

Huajin Securities

Buy

Initiation: domestic PEEK leader, import substitution

14 Oct 2025

Everbright Securities

Accumulate

10 kt integrated project

17 May 2026

Everbright Securities

Accumulate

Project signing

27 Jun 2026

Guotai Junan International (HK) / "Global Fortune"

No rating shown

FY2025 review

Per-Share Data and Dividends & Capital Returns

MetricFY2023FY2024FY2025

DPS (CNY)

0.200.200.20

Total payout (CNY Mn)

24.3424.3424.34

Payout ratio (%)

44.661.95205.0

Analyst Conclusions

Management guidance

  • No numeric guidance.

  • Qualitative statements:

    • Commitment to new applications and faster order release (IR, 30 Sep 2026).

    • Phased build of Zhangjiagang over 2–4 years.

    • Expected short-term earnings pressure from depreciation and qualification lags, with long-term margin gains from monomer self-supply and mix upgrade (Inquiry Reply Q7).

Consensus growth expectations

No published consensus is available. Industry forecasts imply Chinese PEEK market growth of about 17.8% per year (2025–2030). Joinature's realised volume growth was +11.8% in 2025 and about 0% in H1 2026 (revenue basis).

Bull case

  1. Capacity-constrained leader in a fast-growing market. Utilisation was 102% and coarse powder was rationed internally, so flat H1 2026 revenue partly reflects a supply ceiling. Phase II deep-processing capacity (from Sep 2026) and the first Zhangjiagang phase could unlock volume into China's demand, which grew at a 38% CAGR over 2012–2024.

  2. Structural margin upside from integration. Gross margin already reached 50.6% in Q1 2026. Self-made monomer, about 50% of PEEK cost, plus scale could make Joinature the global cost leader while Victrex's Panjin plant struggles at about 3% utilisation.

  3. Optionality in premium niches. Six registered medical devices, a GMP plant and capitalised medical R&D position the company for orthopaedic volume-based procurement, where domestic materials gain share. Each 1% shift of China's medical PEEK into its grades carries outsized margin. Net cash of about CNY 0.4–0.5 bn funds the early phases without dilution.

Bear case

  1. Commoditisation ahead. 38,300 t/y of announced capacity, including a 12,000 t/y entrant (Ningbo Huaxiang) and an 8,000 t/y DFBP supplier moving downstream (Xinhan), dwarfs 2026E Chinese demand of 4,358 t. Customers are already building in-house capacity. The 2024 price cut may be a preview.

  2. Operating de-leverage. Opex is already about 98% of revenue. The 10 kt project adds about CNY 68.6 M per year of depreciation and amortisation and about CNY 17.9 M per year of interest (capitalised only during construction). Without revenue doubling, losses widen through 2027–2029 and impairments become plausible.

  3. Governance and capital-allocation signals. Dividends exceeded earnings, a debt-funded buyback runs alongside an acting-CFO share sale, the controller's placement was withdrawn, auditors changed three times, and the SSE questioned customer quality. Together these suggest weak capital discipline at a moment of maximum capex.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhy it matters
By 31 Oct 2026Q3 2026 resultsWhether revenue re-accelerates and losses narrow
≈30 Oct 2026Buyback completion amountDelivery vs the CNY 50 M floor
Q4 2026Phase II deep-processing plant commissioningVolume capacity vs depreciation onset
Q4 2026 – H1 2027Zhangjiagang approvals (filing, EIA, hazardous-process review) and first loan drawdownsProject feasibility and leverage path
≈Sep 2026 – Mar 2027Controller lock-up expiry (36 months, possibly extended 6 months)Share overhang
OngoingASP trend and DFBP pricesMargin sustainability
OngoingMedical and semiconductor revenue disclosureMix-upgrade proof points
2,027FY2026 annual report; auditor continuityGovernance signal
OngoingCompetitor ramp-ups (Victrex Panjin, Pengfulong, Junhua, Xinhan, Huaxiang)Pricing environment

Analyst verdict

Jilin Joinature is a technically credible, strategically important but financially fragile company. Operationally it has done what a Chinese specialty-materials champion should:

  • It mastered a polymer long under Western export control.

  • It wrote the national standard.

  • It reached 1,000 t/y and ran its plant above nameplate.

  • It lifted gross margin to the mid-40s and then about 50% even after cutting prices.

Its disclosures in the June 2026 Inquiry Reply are unusually candid and show a management team that understands the capacity race it has entered.

The equity, however, prices in success that the financials do not yet support. At about CNY 29 per share the company trades near 10x sales, roughly 3x book and hundreds of times FY2025 earnings, while it is now loss-making. Revenue growth stalled in H1 2026 and operating cash flow is negative. The strategic response is to multiply capacity elevenfold with about CNY 1.2 bn of spending, roughly CNY 510 M of it borrowed. It does so into an industry where announced additions already approach 40,000 t/y against a Chinese market of about 4,000 t.

History favours incumbents with process know-how: Victrex's own China plant produced only 50 t in its first year. That gives Joinature a real but time-limited advantage. The decisive variables over the next 12–24 months are three: whether revenue resumes double-digit growth as Phase II capacity arrives, whether the medical and semiconductor grades turn from pilot sales into tens of millions of revenue, and whether governance stabilises around permanent finance leadership and consistent capital allocation.

Verdict: Neutral / high-risk. It is a strategically well-positioned asset with an attractive long-term thesis on Chinese PEEK import substitution and monomer integration, but near-term earnings, cash flow and governance signals argue for waiting for evidence of profitable volume growth before underwriting the 10 kt expansion. A more constructive stance would be warranted on two quarters of revenue growth above 15% with positive operating cash flow, or on a material de-rating toward 1.5–2x book.


Data current to filings published through early October 2026. The live share price for 7 Oct 2026, FY2025 executive compensation, the controllers' exact shareholdings, full-year geographic splits, capex and EBITDA were not verifiable from retrievable primary sources and are marked accordingly.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleNotesSource

Xie Huaijie (谢怀杰)

Chairman; legal representative and "person in charge"

Co-actual controller. Was proposed subscriber in the terminated 2026 private placement. Third-party aggregators list him as CEO (Simply Wall St shows "Huajie Xie").

Board notices; Q1 2025 report

Yang Liping (杨丽萍)

Non-independent director; acting CFO (代财务总监), head of accounting

Holds 600,700 shares (0.49%). Announced a share-sale plan for 3 Aug–2 Nov 2026.

Q1 2025 report; buyback notice

Bi Xin (毕鑫)

Non-independent director

Co-actual controller

Board notice Jul 2024; Lixinger

Xie Yuning (谢雨凝)

Non-independent director

Co-actual controller; represented the company at the Zhangjiagang signing

Xinhua Finance

Li Zhenfang (李振芳)

Non-independent director

Former officer at IPO; lock-up extended then released Mar 2025

Notice 2025-003

Gao Fang (高芳)

Non-independent director

IPO-era board secretary / contact person

IPO notice; Notice 2025-003

An Yaren (安亚人)

Independent director

—

Board notice Jul 2024

Su Zhiyong (苏志勇)

Independent director

—

Board notice Jul 2024

Zhou Baicheng (周佰成)

Independent director

—

Board notice Jul 2024

Executive Leadership Team

NameRoleNotes

Xie Huaijie

Chairman / principal executive

See above

Yang Liping

Acting CFO

The "acting" designation indicates the CFO post has not been permanently filled

Wang Mingzhuo (王明卓)

Head of accounting department

Q1 2025 report

New board secretary

Appointed 17 Jul 2026

—

Board & Management Changes

DateChangeContext

Jul 2024

Fourth board elected (6 non-independent, 3 independent)

Scheduled expiry of third board on 12 Jul 2024

17 Jul 2026

New board secretary appointed

Same meeting terminated the controller's private placement

Ongoing

Acting CFO arrangement (Yang Liping)

Permanent CFO not named

Major Shareholders

RankHolderShares% of total
1

Liu Guoliang (刘国梁)

2,805,0502.31
2

Wang Xiuyun (王秀云)

2,607,3002.14
3

Haitong Innovation Securities Investment Co. (sponsor co-investment vehicle)

1,318,6171.08
4

Guotai Jiatai equity pension product – China Merchants Bank

1,071,3020.88
5

Yang Liping (director, acting CFO)

600,7000.49
6

Chen Zhanhui (陈展辉)

547,1430.45
7

Jing Tao (荆涛)

525,0580.43
8

Wang Yanlong (王彦龙)

465,6810.38
9

Yang Jun (杨军)

456,8340.38
10

Changchun Science & Technology Venture Capital Co.

449,8700.37

Competitive Landscape

Key Competitors

CompanyCountryExisting PEEK capacity (t/y)Planned (t/y)Positioning

Victrex plc (VCT.L)

UK (+ China JV)

7,150—

Global leader and PEEK inventor; Invibio medical; aerospace, auto, electronics

Victrex Panjin (JV with Yingkou Xingfu)

China (Liaoning)

1,500—

China-for-China plant; produced ≈50 t in FY2025 (Sep YE)

Syensqo (ex-Solvay Specialty Polymers; KetaSpire)

Belgium / India

2,500—

High-temperature, chemical resistance; oil and gas, electronics

Evonik (VESTAKEEP)

Germany / China

1,800—

Low moisture uptake; strong in medical implants

Zhejiang Pengfulong (鹏孚隆)

China

1,500 (design)

—

Domestic challenger

Junhua Co. / Shandong Junhao (君华股份/山东君昊)

China

1,500 (design)

1,100

Domestic challenger

Jilin Juke High-Tech (吉林聚科高新)

China

7001,000

Changchun neighbour

Changchun Jida Special Plastics (长春吉大特塑)

China

500—

Jilin University spin-off lineage

Wote Advanced Materials (沃特股份, 002886.SZ)

China

500500

Diversified specialty polymers (>CNY 2 bn revenue)

Kingfa Sci & Tech (金发科技, 600143.SH)

China

400—

Compounding giant

Shandong Haoran Special Plastics

China

300—

Small producer

Xinhan New Materials (新瀚新材)

China

2008,000

Also a DFBP supplier; moving downstream

Mitsubishi Chemical

China (Changshu)

—600

Entrant

Ningbo Huaxiang (宁波华翔)

China

—12,000

Auto-parts group entering PEEK

Guoen (国恩股份)

China

—1,000

Entrant

Huitong (会通股份)

China (Shanghai)

—600

CNY 81 M high-temperature nylon plus PEEK polymerisation project (Oct 2025)

Baihehua (百合花), Dayang Bio (大洋生物), Jilin Yihong

China

—

1,000 / 2,000 / 500

Entrants

Jilin Joinature

China

1,00010,000

Domestic volume leader

Total (company's table)

—

19,550

38,300

—

Peer Comparison FY2025

MetricJilin Joinature (FY2025, Dec YE)Victrex (FY2025, Sep YE)Wote Advanced Materials (FY2025)Haohua Technology (FY2025)

Revenue

CNY 309.2 M

GBP 292.7 M (≈CNY 2.8 bn)

CNY 2 bn (company description)

CNY 10 bn (company description)

Revenue growth

+11.6%

+1% (+3% cc)

Increased (per Inquiry Reply)

Increased (per Inquiry Reply)

Gross margin

44.05%45.3%

Below Joinature, declining

Below Joinature

Profit

NP CNY 11.9 M

Underlying PBT GBP 46.4 M (−21%); reported NP GBP 27.8 M

NP increased

NP increased

R&D intensity

15.25%———

PEEK capacity (t/y)

1,000

7,150 (+1,500 China JV)

500

n/a (fluorochemicals; DFBP-adjacent)

Recent Developments

--

Company Snapshot

$43M

Revenue

464

Employees

2006

Founded

Jilin, China

Headquarters

SWOT Analysis

Strengths

  • Domestic volume leadership. 1,079.84 t sold in 2025 (+11.84%), the first Chinese producer to pass 1,000 t; the company claims to out-sell Victrex in China (FY2025 AR; Inquiry Reply).
  • Rising gross margin through a price war. Gross margin went 39.48% → 40.08% → 44.05% (2023–2025) despite an 11% ASP cut in 2024, and reached 50.64% in Q1 2026 (Inquiry Reply).
  • Full utilisation. Capacity utilisation was 102.43% in 2025, with coarse powder rationed internally (sell-through 4.17%), evidence of demand above capacity (Inquiry Reply).
  • Fortress balance sheet. Liabilities/assets were 9.44% (Mar 2026); cash plus structured deposits about CNY 525 M; unused credit lines about CNY 563 M at end-2025 (Inquiry Reply Q7).
  • Proven process technology. A 5,000 L reactor process, a 7-year ramp history and a role as first drafter of GB/T 41873-2022 (FY2024 AR).
  • Medical validation achieved. NMPA master file M2024156-000, six registered devices using PEEK-LISCIEX, ISO 13485 and a GMP workshop (Inquiry Reply Q5).

Weaknesses

  • Profit collapse. Net profit went CNY 54.6 M → 39.3 M → 11.9 M (2023–2025), then a net loss of CNY 13.0 M in H1 2026 (cfi.cn).
  • Subsidiary losses. Parent NP of CNY 52.1 M vs consolidated NP of CNY 11.9 M in FY2025 implies about CNY 40 M of subsidiary drag (Inquiry Reply Q1; derived).
  • Weak cash conversion. FY2025 OCF was −CNY 37.7 M against NP of +CNY 11.9 M; H1 2026 OCF was −CNY 16.0 M (cfi.cn).
  • Low-value mix. Pure resin is 70% of revenue; medical revenue was only CNY 5.17 M cumulatively over three years; semiconductor-modified grades produced CNY 0.44 M (Inquiry Reply Q5).
  • Slow inventory turns and growing WIP. Turnover of 1.21x; semi-finished inventory up from CNY 18.3 M to CNY 50.8 M (2023–2025); no write-down provisions (Inquiry Reply Q1).
  • Governance flux. Three auditors in three years; an acting CFO; a new board secretary in July 2026; a controller placement launched and withdrawn within 11 weeks.

Opportunities

  • Chinese market growth. CNY 2.2 bn (2025) to CNY 5.0 bn (2030), a 17.8% CAGR (Inquiry Reply).
  • Import replacement. About 1,100 t of 2024 imports, concentrated in high-end grades (Inquiry Reply).
  • Monomer integration. DFBP is about 50% of cost; the planned 2 kt monomer plant could lower unit costs materially (Inquiry Reply).
  • Humanoid robots and NEV 800 V. New volume pools; the robot R&D project already has partial adoption (Inquiry Reply Q5).
  • Export markets. Below 1% share today; Feddersen distribution and the EU warehouse give a low base to grow from (Plasteurope; FY2025 AR).
  • Victrex's China stumble. Panjin produced only about 50 t on 1,500 t design capacity in FY2025, with an estimated £8 M annualised loss (Victrex FY2025 call; MarketBeat summary).

Threats

  • Capacity glut. 38,300 t/y of planned additions vs 2026E Chinese demand of 4,358 t (Inquiry Reply).
  • Customer self-supply. Cited explicitly for weak Q1 2026 pellet sales (Inquiry Reply Q1).
  • Execution and financing risk at the 10 kt project. About CNY 510 M of new debt, and depreciation and amortisation of about CNY 68.6 M per year post-completion (22% of FY2025 revenue) (Inquiry Reply Q7).
  • Hazardous-process permitting. Monomer synthesis involves diazotisation and chlorination processes needing provincial review (Inquiry Reply Q7).
  • Raw-material cycle reversal. The DFBP decline has nearly stopped (−3.28% in 2025); suppliers such as Xinhan are moving into PEEK themselves (Inquiry Reply).
  • Equity overhang and volatility. About 42.5% of shares restricted around the 3-year anniversary; margin balance about 10% of free float; steady insider and early-holder selling (Lixinger; filings).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
26 Apr 2025FY2024 annual report: revenue CNY 277 M (−5.05%), NP CNY 39.3 M (−27.99%); CNY 0.20/share dividend (62% payout)Confirms price-cut year
26 Apr 2025Q1 2025: revenue +64.81% YoY on volumeStrong rebound from a weak Q1 2024
26 Apr 2025Board approves cash management of idle IPO and own fundsTreasury income supports profit
Mar–Jun 2025Wang Xiuyun sells under a 1% planSupply overhang
28 Aug 2025H1 2025: revenue CNY 131.3 M, NP CNY 7.0 MProfit compression visible
25 Aug–28 Nov 2025Second Wang Xiuyun sale plan; holder group falls below 5% (equity change report, Sep 2025)Early investor exit
14 Sep 2025Huajin Securities initiates at "Buy"First coverage
14 Oct 2025Everbright Securities "Accumulate" note on 10 kt integrated projectPlan becomes public
31 Oct 2025Q3 2025: 9M revenue CNY 207.0 M, NP CNY 10.4 M; OCF −CNY 56.7 MCash-flow concern
Dec 2025Victrex FY2025 results: Panjin (China) plant under-utilised (≈50 t produced vs 1,500 t design)Main rival's China ramp is slow, which is positive for Joinature near-term
Apr 2026K.D. Feddersen appointed EU distributorExport push
28 Apr 2026FY2025 AR: revenue CNY 309.2 M (+11.6%), NP CNY 11.9 M (−69.8%), deducted NP CNY 4.9 M (−80.2%); volume 1,079.84 tGrowth without profit
28 Apr 2026Q1 2026: revenue CNY 65.6 M (+1.65%), net loss CNY 4.8 MFirst quarterly loss since listing
29 Apr 2026Private placement plan to chairman (≤CNY 303 M at CNY 26.35)Controller support signal
14 May 2026Zhangjiagang 10 kt PEEK plus 2 kt monomer project signed (CNY 1.2 bn)Transformational capex
17 May 2026Everbright reiterates "Accumulate"–
Late May–Jun 2026SSE inquiry letter on FY2025 AR (上证科创公函【2026】0221号)Regulatory scrutiny
18 Jun 2026Inquiry Reply published: discloses capacity utilisation 102%, capex detail, ≈CNY 510 M debt need, competitor capacity tableMajor disclosure event
27 Jun 2026GTJA (HK) research noteCoverage broadens
Late Jun 2026Stock gains about 10% in a session to CNY 36.57 (cfi.cn snapshot)High volatility
10 Jul 2026Acting CFO Yang Liping files share-sale plan (3 Aug–2 Nov 2026)Insider selling
17 Jul 2026Private placement terminated; new board secretary; Jiangsu project subsidiary (CNY 100 M) approvedFunding strategy shift
24 Jul 2026Close CNY 24.70; triggers buyback criteria (20-day fall ≥20% and price below 50% of 1-year high close)Sharp drawdown
30–31 Jul 2026Buyback approved: CNY 50–100 M, ≤CNY 48.94, 3 monthsValue support
5 Aug 2026Industrial Bank ≤CNY 90 M buyback loan commitmentDebt-funded buyback
6 Aug 2026Continued supply
29 Aug 2026H1 2026: revenue CNY 131.7 M (≈flat), net loss CNY 13.0 M; OCF −CNY 16.0 MLosses deepen in Q2
Sep 2026IPO Phase II deep-processing plant and R&D centre due to reach usable stateDepreciation step-up
20 Sep 2026Third anniversary of listing; nominal end of 36-month controller lock-upOverhang watch
30 Sep 2026IR record: management acknowledges flat H1 revenue and cites new applications as growth driversNo guidance

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue rose from CNY 203 Mn in FY2021 to CNY 309.2 Mn in FY2025.
Jilin Joinature Polymer Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue203248.1291.9277309.2
Cost of revenue——176.7166173
Gross profit——115.2111136.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.